Conclusion
The SARS-CoV-2 virus, which is the cause of COVID-19 infection, has the
ability to reduce several parts of the brain. Axonal and transsynaptic transport are
most likely used by the virus to reach the CNS through the olfactory
nerve. The second way the virus might enter the brain is the hematogenous route. According to
prior study, COVID-19 infection can negatively affect glial cells, which leads to negative side effects
such agitation, altered consciousness, headaches, and dizziness, or even mental and neurodegenerative disorders.
Paxlovid has been approved by
FDA in the treatment of COVID-19 infection. The findings suggest that Paxlovid diminishes not only the risk of
hospitalization or death from a coronavirus infection but also the risk
of long-term illness.